-The Telegraph Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched. But the court described its scheme of classifying people on the basis of their incomes as “too complicated” and again urged the company to reduce prices. Whatever the scheme, the end result...
More »SEARCH RESULT
Patients lose out to Patents & profits -Deepa Kurup
-The Hindu A 2012 WHO study ranks India third — behind Myanmar and Bangladesh — among countries that fail to provide health cover to people. A 2011 study reported in The Lancet on ‘Healthcare and equity’ confirms this: every year, at least 39 million people here fall into poverty due to private out-of-pocket health expenditure. A vast majority of Indians do not have access to healthcare or essential drugs. By the...
More »Natco targets drugs ripe for compulsory licensing-Viswanath Pilla
-Live Mint Natco Pharma Ltd, which has started selling a generic version of Bayer AG’s patented cancer treatment Nexavar in India at a fraction of the price charged by the German firm, plans to use the so-called compulsory licensing route to try and win the right to copy more patented drugs, said vice-chairman and chief executive officer Rajeev Nannapaneni. The Hyderabad-based company has already identified the patented drugs for which it will...
More »European Parliament rejects Anti-Counterfeiting Trade Agreement-Ankur Paliwal
Act makes it possible to seize and destroy even legitimately produced generic drugs exported from India to poor countries It was a triumphant moment for public health campaigners when members of the European Parliament voted against the Anti- Counterfeiting Trade Agreement (ACTA) on July 4. ACTA is a plurilateral pact, designed to protect against counterfeiting of products, including medicines. ACTA, primarily drafted and secretly negotiated by the US, was signed on October...
More »More nations adopting Indian intellectual property regulations for drug manufacturing-Khomba Singh
-The Economic Times A growing number of countries are adopting India's intellectual property regulations, which give enough flexibility to local companies to produce generic versions of popular drugs to safeguard public health. Although multinational companies have criticised India for being lax in enforcing intellectual property (IP) laws, countries such as China, Argentina and the Philippines are adopting similar provisions. Last month, China amended its IP laws, allowing local companies to produce low-cost versions...
More »